This company has been marked as potentially delisted and may not be actively trading. Obalon Therapeutics (OBLN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock OBLN vs. CERS, TCMD, NYXH, NVRO, DRTS, SKIN, CATX, BWAY, OSUR, and SGHTShould you be buying Obalon Therapeutics stock or one of its competitors? The main competitors of Obalon Therapeutics include Cerus (CERS), Tactile Systems Technology (TCMD), Nyxoah (NYXH), Nevro (NVRO), Alpha Tau Medical (DRTS), Beauty Health (SKIN), Perspective Therapeutics (CATX), BrainsWay (BWAY), OraSure Technologies (OSUR), and Sight Sciences (SGHT). These companies are all part of the "medical" sector. Obalon Therapeutics vs. Cerus Tactile Systems Technology Nyxoah Nevro Alpha Tau Medical Beauty Health Perspective Therapeutics BrainsWay OraSure Technologies Sight Sciences Obalon Therapeutics (NASDAQ:OBLN) and Cerus (NASDAQ:CERS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, community ranking, risk and dividends. Which has preferable earnings & valuation, OBLN or CERS? Obalon Therapeutics has higher earnings, but lower revenue than Cerus. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioObalon Therapeutics$1.59M30.07-$12.33MN/AN/ACerus$185.14M1.31-$37.49M-$0.10-12.65 Is OBLN or CERS more profitable? Cerus has a net margin of -11.60% compared to Obalon Therapeutics' net margin of -776.76%. Cerus' return on equity of -40.55% beat Obalon Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Obalon Therapeutics-776.76% -161.38% -83.58% Cerus -11.60%-40.55%-11.12% Which has more volatility and risk, OBLN or CERS? Obalon Therapeutics has a beta of -1.23, suggesting that its stock price is 223% less volatile than the S&P 500. Comparatively, Cerus has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. Does the MarketBeat Community prefer OBLN or CERS? Cerus received 324 more outperform votes than Obalon Therapeutics when rated by MarketBeat users. Likewise, 72.34% of users gave Cerus an outperform vote while only 46.42% of users gave Obalon Therapeutics an outperform vote. CompanyUnderperformOutperformObalon TherapeuticsOutperform Votes24646.42% Underperform Votes28453.58% CerusOutperform Votes57072.34% Underperform Votes21827.66% Do institutionals and insiders hold more shares of OBLN or CERS? 18.6% of Obalon Therapeutics shares are owned by institutional investors. Comparatively, 78.4% of Cerus shares are owned by institutional investors. 8.1% of Obalon Therapeutics shares are owned by company insiders. Comparatively, 5.6% of Cerus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts rate OBLN or CERS? Cerus has a consensus target price of $3.50, indicating a potential upside of 176.68%. Given Cerus' stronger consensus rating and higher possible upside, analysts clearly believe Cerus is more favorable than Obalon Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Obalon Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cerus 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to OBLN or CERS? In the previous week, Cerus had 2 more articles in the media than Obalon Therapeutics. MarketBeat recorded 2 mentions for Cerus and 0 mentions for Obalon Therapeutics. Cerus' average media sentiment score of 0.94 beat Obalon Therapeutics' score of 0.00 indicating that Cerus is being referred to more favorably in the news media. Company Overall Sentiment Obalon Therapeutics Neutral Cerus Positive SummaryCerus beats Obalon Therapeutics on 13 of the 17 factors compared between the two stocks. Get Obalon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OBLN vs. The Competition Export to ExcelMetricObalon TherapeuticsSurgical & Medical Instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.81M$4.41B$5.34B$8.46BDividend YieldN/A45.22%5.29%4.18%P/E Ratio-3.5329.2826.8819.78Price / Sales30.0772.30398.48138.40Price / CashN/A51.0838.2534.64Price / Book7.956.186.764.54Net Income-$12.33M$66.90M$3.22B$247.85M Obalon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OBLNObalon TherapeuticsN/A$4.77+0.2%N/A+2,431.9%$47.81M$1.59M-3.532CERSCerus2.9012 of 5 stars$1.32-0.8%$3.50+165.2%-31.5%$252.33M$185.14M-12.00290Positive NewsGap DownTCMDTactile Systems Technology3.4704 of 5 stars$10.40flat$16.00+53.8%-24.0%$241.78M$293.16M14.86980Positive NewsNYXHNyxoah2.6259 of 5 stars$6.79+7.9%$14.50+113.5%-8.8%$231.27M$4.52M-3.63110Gap UpHigh Trading VolumeNVRONevro0.189 of 5 stars$5.85+0.1%$5.36-8.3%-37.7%$224.32M$408.52M-3.091,090News CoverageDRTSAlpha Tau Medical1.9769 of 5 stars$3.10+11.1%$8.00+158.1%+21.3%$218.18MN/A-7.2180News CoverageAnalyst RevisionGap UpHigh Trading VolumeSKINBeauty Health0.2336 of 5 stars$1.64-5.7%$1.42-13.6%-32.9%$217.93M$322.47M-3.901,030Trending NewsGap DownCATXPerspective Therapeutics3.4096 of 5 stars$2.73+3.8%$12.50+357.9%-84.0%$202.64M$1.43M0.0070BWAYBrainsWay3.2766 of 5 stars$10.65+7.5%$14.25+33.8%+97.2%$200.99M$43.46M106.51120News CoveragePositive NewsAnalyst RevisionOSUROraSure Technologies3.1621 of 5 stars$2.63+8.2%$3.00+14.1%-42.9%$196.72M$161.63M17.53840SGHTSight Sciences3.0266 of 5 stars$3.27-7.9%$3.92+19.8%-38.2%$183.52M$78.11M-3.21210Positive NewsGap Down Related Companies and Tools Related Companies CERS Competitors TCMD Competitors NYXH Competitors NVRO Competitors DRTS Competitors SKIN Competitors CATX Competitors BWAY Competitors OSUR Competitors SGHT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OBLN) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe “supermetal” that could power AIWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Obalon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Obalon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OBLN Stock Free OBLN Stock Alerts